Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03143153) enrolled 970 people across three treatment groups: 325 received a combination of nivolumab and ipilimumab (two immunotherapy medicines), 321 received nivolumab combined with chemotherapy, and 324 received chemotherapy alone. The trial was measuring two main things: how long participants lived overall (called "overall survival"), and how long they lived without their cancer growing or spreading (called "progression-free survival," meaning the time before the disease got worse or the person passed away). These main measures were looked at first in participants whose tumours showed a particular protein marker (called PD-L1), and then across all participants. The reported data shows that, among participants whose tumours had the PD-L1 marker, the median overall survival — that is, the midpoint time at which half the participants in each group had passed away — was reported as approximately 13.7 months for the nivolumab-plus-ipilimumab group, 15.4 months for the nivolumab-plus-chemotherapy group, and 9.1 months for the chemotherapy-alone group. The median time before disease worsened (progression-free survival) in this same group was reported as approximately 4.0 months, 6.9 months, and 4.4 months respectively. Across all participants regardless of PD-L1 marker status, the reported median overall survival figures were approximately 12.7, 13.2, and 10.7 months for the three groups, and median progression-free survival was approximately 2.9, 5.8, and 5.6 months. The reported data also shows that the proportion of participants whose tumours shrank noticeably (called the "objective response rate") varied across groups and across different subgroups measured in the trial, with figures ranging from around 20% to 53% depending on the group and the subgroup being reported. The reported data includes multiple sets of response rate figures, likely reflecting different subgroups, though the data as submitted does not label each set separately. No further breakdown of those figures was provided in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37139963) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Oesophageal Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma or adenosquamous cell carcinoma), confirmed through a lab test of tissue
- You are at least 18 years old (male or female)
- Your esophageal cancer cannot be removed with surgery or treated with the goal of a cure using chemotherapy and radiation, and it is advanced, has come back, or has spread to other parts of the body
- You are either fully active, or if your activity is somewhat limited, you are still able to walk and do light tasks such as light housework or office work
- You are willing to provide a tumor tissue sample — either from a previous surgery or biopsy done within the last 6 months, or a new sample taken before treatment begins
Who may not be able to join:
- You have cancer that has spread to the brain or spinal cord and is causing symptoms or needs treatment
- You have an active autoimmune disease (a condition where your immune system attacks your own body)
- You have a serious or uncontrolled medical condition or an active infection
- You have HIV or AIDS
- You have tested positive for hepatitis B or C, showing a current or ongoing infection
Important note: There may be additional eligibility requirements not listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival (OS) in Participants With Tumor Cell PD-L1; Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.